New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, ...

An expert discusses that while the liso-cel trial did not show a statistically significant overall survival benefit—likely ...

An expert discusses how the ZUMA-7 trial marked a pivotal shift in the treatment of primary refractory diffuse large B-cell lymphoma by demonstrating that second-line CAR T-cell therapy not only ...

Panelists discuss how the treatment landscape for treatment-naive patients with chronic lymphocytic leukemia (CLL) is rapidly ...

The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed ...

Panelists discuss how the updated SEQUOIA Arm C data demonstrate that zanubrutinib monotherapy achieves a remarkable 72% ...

Panelists discuss how real-world evidence studies from databases like Flatiron demonstrate that second-generation Bruton ...

Katherine McDaniel, MD, discusses the barriers to fertility preservation access for patients diagnosed with cancer.

Nina Balanchivadze, MD, FACP, discusses how inclusive research begins at the community level by addressing barriers to trial ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials.

Katherine McDaniel, MD, a reproductive endocrinologist, discusses the key takeaways for oncologists treating patients of reproductive age.